Member Info for CJ39

DSFiat, you don’t still have a million shares in EVG do you?

Tivman, I can’t find that piece of information. If you’re right then I stand corrected but even so $500,000 probably only funds a couple of months extra, it’s unlikely to avert a share placing.

Barf, you are fantasist, you put down this as a strong buy, you criticise people like Alf, radar and myself for posting critical comments about EVG, you state you have every confidence in a successful outcome here. You’re writing nonsense. EVG three years ago today was trading at 14.15p. If you bought £10,000 worth of shares at 14.15p three years ago it would today be worth £1725. You think people aren’t entitled to post critical comments of the business ? You say this is a strong buy? There will be no money coming into the company for the next year, not a sausage. A third share placing will happen next year in the space of four years, diluting the shares so much that it will become impossible for people to make their money back.

You need to realise that this is a messageboard about EVG shares and people are entitled to post their views. I get that you don’t believe in free speech and you should censor anyone who does not think the way you do but thank goodness the world doesn’t work like that.

Baf and Tivman, when you put it like that I see what you mean. I’m been very critical of EVG of late, of the finances, of the decisions made previously by the board to not raise far more money when the share price was higher, of posters here who are invested and don’t want negativity which may influence others to sell.

I’d like to take this opportunity to apologise… to absolutely nobody. It’s a messageboard about investing in shares for gods sake, stop being so ridiculous.

Kingalf, are you going to let him speak to you like that?

Tivman, you’re absolutely right, I could be wrong, after all I was wrong in investing here at 5.3p and 4.5p, although I feel like I know far more about EVG and their situation now compared to last October.

Don’t get me wrong, I think EVG have something in SFX-01, it’s not the drug I think is a problem it’s simply the cash flow. EVG has done a share placing in April 2019 and February 2021. It just seems inevitable another one is coming by next Spring.

Ontarget - no offence taken. I am hardly crying but it is frustrating losing over £3k as I invested hoping to make money not lose it. I am sure you are the same? My main holdings are Aviva and Flutter.

The point of a message board is surely to have discussion about the company. Surely you don’t want messageboards to be just deluded rampers? I like to think people like myself, radar and Alf will prevent people losing money. You would want that if you were looking at a share on here wouldn’t you?

Tricky matters, what is wrong with you? Are you ok? You’re like a child. This is a message board about EVG. I’m posting my thoughts about the company, you’re crying like a baby because I’m not posting delusional positives. How much have you got invested here?

I agree with Kingalf. Last time they did a share placing was in Feb 2021, in the final results for the year ending 31/03/2020 they had £4m in cash.

At the time of the placing EVG had cash of £1.5m in the bank. Therefore with £5m in the bank as at 31/03/2023 if a share placing happens when they are down to the last £1.5m, if they spend anywhere between £3m and £4m in the 2023/24 year the share placing is likely around Easter 2024.

There is absolutely no money incoming, no money from Juvenescense and the Stalicla payments not expected until late 2024. A share placing at a price of 1p to 2p will be a disaster, it will make it impossible to make any money here. The mistake EVG made was not raising far more money in the Feb 2021 placing.

If EVG had plenty of money behind them I would have stayed invested as SFX-01 looks to have potential but unless something major happens to avoid a placing this is cooked.

I’m not here to troll, I’m here posting honest thoughts. I lost over £3k here, I’m very disappointed as I feel we were lied to. We were told the $6m from Stalicla would arrive in 2023 which would give enough funds to last 2 years and avert a share placing until 2025.

Decent cash runway? They had £5.0m as at 31/03/2023. They posted a £4m loss in the year ending 31/03/2023. If they burn through money at the same rate they will run out of cash by the end of May 2024.

What cash is arriving in staged payments? Nothing is now due from Juvenesense and it says the $5.5m from Stalicla is anticipated by the end of 2024. Therefore a share placing is inevitable and if they are to raise £10m like last time at even 2p a share it will increase the number of shares from 275m to 775m which means if EVG was to reach say £75m in market cap, the share price would only be about 10p. Come on, you must see that running out of cash and a share placement ends this as an investment opportunity.

Very amusing DSFiat, I shall miss your humour, you’ve been a good poster on here. I know there are people invested who don’t want to hear negatives, it happens on lots of the AIM messageboards and with footballindex so I don’t blame you for your sly dig. I know you’ll be happier if you’re with people posting positive comments so I’ll be sure to leave you to it.

Thanks Alf. Thanks for all the warnings, I always had time for your posts, I say it all the time these message boards are full of rampers and people hostile towards people who are critical or wary of a company and it is rubbish, what’s the point of a messageboard if you can’t get honest and balanced views? The people who post honest negative posts are the ones who will potentially save people a fortune. The rampers and blindly positive people will cost you a fortune.

I’m disappointed to lose over £3k here but I did make quite a lot more than that in the previous years elsewhere. As you say on face value it looked a winner this one. I’ll be watching as I am curious to see how this pans out. Good luck with your investments.

I sold all my shares in EVG this week. I bought in after the Stalicla deal was announced last October. I bought in at 5.3p and again a few months later at 4.5p. My total outlay was £6500 and I lost £3200, gutted.

I feel like I messed up as I clearly didn’t know how slow things move here but also unhappy that we were lied to. In the RNS announcing the Stalicla deal and the half year report 08/12/2022 we were told Evgen would receive $6m by the end of 2023 which would extend the cash runway until 2025 which would give Evgen the time to make progress with other clinical trials and potentially create new income streams. In the final results in 07/06/2023 the remaining $5.5m we were due to receive by end of 2023 is now expected by the end of 2024 without any explanation. That is a major problem as the company now appears to be heading for a share placing in the first half of 2024 with no income on the cards in the next 12 months.

I’m really disappointed by how this has gone. When I invested I thought I found an amazing share with money going to be rolling in and advances in clinical trials pushing the share price up steadily. I was sure I’d double my money here.

I am going to soon give up investing in shares, once my only other holding in Aviva reaches a price that breaks me even I’m closing my share account. The markets are awful, I will be happy to put my money in savings accounts or premium bonds where it’s safe and will increase.

My advice to those here is seriously consider selling before a share placing brings the share price down further and dilutes the shares enormously. In the last share placing in Feb 2021 they raised around £10m by issuing 125m shares. There are 275m shares in issue at the moment. But if they want to raise £10m at a price of 1.5p which looks likely, it will need to issue 666m shares, bringing the total number of shares to 940m. If the company does reach £100m in value in time, with the current 275m shares in circulation the share price would be 36p.

But with 940m shares in circulation, if the company reached £100m in value, the share price would only be worth 10.6p. A share placing will destroy the potential here.

It’s a strong sell for me.

Tricky matters, in the half year report on 8/12/2022:

Substantial out-licensing deal signed with STALICLA SA for neurodevelopmental disorders with total milestones of $160.5m, double digit royalties. Up to $6m in initial milestones to be received before end 2023.

In the final results on 07/06/2023:

· Further milestones from STALICLA collaboration expected during the year with up to $5.5m anticipated by 31 December 2024.

Did you notice the date of the milestone payments became a year later?

I’m a shorter you say (please don’t be silly like that) - I bought in thinking we would have a payment coming in this year which would extend the cash runway for a year and also Juvenesense another income stream. Now neither is happening this year.

CEO has never explained why none of the board are buying shares. He claims they can’t for legal reasons. I’ve never heard of such a thing ever.

Only last week in the Q&A they mentioned Juvenesense milestone payments in the next year. Within a week Juvenesense has pulled out. Did they really not know that deal was about to end? Why sugar coat it?

Would you prefer it if I only write positive things and ignored anything that I am critical of?

Kingalf, I’ve always welcomed your’s and radar’s honest criticism of EVG, I hate messageboards where people hound anyone who is critical of a share. I think everyone should apologise to you and radar for how you have been treated on here at times. You’re right, this share is one to stay clear of at this stage, maybe in a few years time if the SFX-01 drug has passed clinical trials and contracts have been agreed to supply the drug then it would be worth investing in. But EVG will continue to burn through money for years to come. There is absolutely no money coming in over the next 12 months. Of course the share price will continue to fall as a placing looms.

I don’t know how trickymatters can think a share placing at 1p is nonsense. We are at 2.8p now and share placing always come at a lower price. How many additional shares will be in circulation to raise say £12m - £15m at 1p?

I do believe EVG could one day be successful but it’s years down the line. It is pointless being invested in EVG at present IMO. I will be selling out.

I’ve been hoping for a RNS with some good news to help this share price as we’ve seen the share price in steady decline since last December but this was not what I was hoping to see. I know it maybe a fairly minor deal in the grand scheme of things but at this moment any income is a god send as we face staring down the barrel of a share placing before too long. But what is more disappointing is that they mentioned Juvenesense in the Q&A just last week, talking about milestone payments from them will help with the cash runway and I am sure they mentioned a $1m payment expected by Juvenesense next year. Did EVG really not know about this coming to an end? And not only that but the RNS sugar coats it as almost a positive. It’s not a positive, we have lost an income stream and why? Was the SFX 01 drug not beneficial to their products?

My problem also with the Q&A is that they talked so positively about the cash runway and again they would not say why they are not allowed to buy shares. The money is running out fast with no signs of any money incoming. The $5.5m expected by Stalicla was expected originally by the end of 2023 which would have given the company more time to conclude clinical trials and get more contracts signed, but now the Stalicla payments are expected (if all goes well) by the end of 2024. How are we going to avoid a share placing with the reserves lasting just one year and no money incoming? A placing would see the share price being diluted to about 1p a share. Even the $5.5m payment that is mentioned would not last more than a year.

EVG could strike the jackpot with the SFX 01 drug with Stalicla and if it’s proven to help treat cancers but everything is so far away. Unless there is some transformative news in the months ahead this is going to lose loads more value.

I agree with the frustration on this share. It’s not Aviva I have a problem with, the results always looks strong and the dividends are good. But the share price struggles, like others have said if something happens the other side of the world the share price here suffers. The Silicon Valley banking problems caused the share price to drop a lot. Today the Japan problems caused us to lose more value even though I bet it’s had no impact on Aviva in reality. Im starting to think I’d rather stick my money in premium bonds and ISAs that are safe and gains value. I’m losing my interest in investing in shares, it’s just full of problems.

I agree, this share is cheap at 390p, nothing has changed since we were trading at 460p, this share always bounces around between 380p and 470p, it is usually held down for a while after the dividend qualifying date. This is one of these shares that when it’s at these levels for a month or two you start thinking will it rise back, is this where we are at. But it will rise. Whilst when it’s doing very well and above 460p you start thinking we’ve seen the last of the 390p days. This share is solid, I’d never sell out at sub 440p as it will return to there before too long.

I remain very optimistic that EVG will come good, I think they have something in SFX-01 which will be successful in treating various disorders and diseases. Long term I believe this will be a money spinner. The short term question is can they get enough money in to avert a share placing?

Alfie, I didn’t think SFX-01 by itself cured these disorders or diseases, I was under the impression that it works in collaboration with other drugs to improve the effectiveness of the primary drug.

Do you think Stalicla thought lets give SFX-01 a go for the fun of it, we’ve got no idea what this white tablet does but we’ll pay them $500,000 up front and $5m once phase 1 is completed to see if it does anything? The chemical compounds of the drug were identified to benefit their primary drug. You seem to think these scientists are a bunch of wallies who just try things for the fun of it.